Genmab A/S is paying $8 billion to acquire Merus NV, gaining rights to the latter’s phase III-stage petosemtamab, a ...

Rhythm Diagnostic Systems SAS (RDS) raised €14 million (US$16.6 million) in a series A funding round for Multisense, its ...

Up to 71% of people carry at least one pathogenic variant that could contribute to development of a heritable disorder in ...

In August 2025, BioWorld logged 95 clinical trial updates across phases I to III, compared to 140 tracked in July and 254 in ...

The U.K. National Institute for Health and Care Excellence unveiled a plan that is designed to provide less cumbersome market ...

Around the globe, fungal infections affect more than 1 billion people and account for several million deaths every year. They ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aria Diagnostics, Electrocore, Eli Lilly, Embleema, Hologic, Minicarm.com, Resonetics, Tandem, ...

Antibodies that bind to sugars on the surface of cancer cells, rather than to proteins, have not yielded satisfactory results so far due to their low binding affinity. However, scientists at the ...

Checkpoint inhibitors have transformed cancer therapy by enhancing immune responses against tumors. However, their effectiveness is limited, as many patients do not respond due to the absence of a pre ...

Shenzhen Bay Laboratory has identified compounds reported to be useful for the treatment of cancer, eye, cardiovascular, metabolic, autoimmune, inflammatory, neurological and dermatological disorders.

Rakuten Medical Inc. is advancing a pipeline of solid tumor therapeutics built on its Alluminox platform worldwide, having ...

Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for ...